Jeffrey Foy

Dr. Jeffrey Foy is the Vice President of Toxicology at PepGen. He previously served as the Executive Director of Toxicology at Dicerna Pharmaceuticals, where he designed and executed nonclinical safety pharmacology and toxicology studies for internal and partnered development assets. Prior to his time at Dicerna, Jeff held various leadership positions at Celgene, where he worked across a number of therapeutic areas, including oncology, inflammation, and immunology. He has made broad contributions to the understanding of the toxicology of oligonucleotide and peptide therapeutics, and his work has been cited in numerous peer-reviewed publications and presentations. He is a Diplomate of the American Board of Toxicology, a member of the Oligonucleotide Therapeutics Society, and Chair of the Oligonucleotide Safety Working Group. Jeff received his Ph.D. in Toxicology from Northeastern University in Boston after obtaining his Bachelor of Science in Biological Sciences at the University of Vermont.